Resources

Malaria progress off trackAccording to the 2025 World Malaria Report, global progress in reducing malaria deaths is falling far short. In 2024, there were 610,000 deaths—more than 3 times the global target—and an estimated 282 million cases. The report highlights intensifying risks to malaria control, including antimalarial drug resistance, parasite gene deletions that undermine diagnostic tests, insecticide resistance that reduces the effectiveness of bed nets, and the invasive mosquito Anopheles stephensi, which poses a serious challenge to urban malaria control. Extreme weather events, shifting temperatures and rainfall, and conflict and instability are also driving outbreaks and disruptions to health services. Meanwhile, global funding for malaria has plateaued at less than half the target set by the Global Technical Strategy, with recent reductions in development assistance severely impacting interventions.PATH’s commitmentPATH is dedicated to reversing stalled progress and addressing these growing threats. Our 2026-2030 strategy prioritizes strong alignment and coordination within the global malaria ecosystem. Central to this strategy are seven core pillars, recognized globally as essential to driving transmission down to zero. These pillars align with the RBM Partnership Big Push Framework, the WHO Global Technical Strategy, and the 2024 Yaoundé Declaration for a Big Push against malaria endorsed by African Ministers of Health.Through coordinated action and strategic alignment, PATH aims to maximize resources and achieve the greatest impact in the fight against malaria.

Sub-Saharan Africa has made remarkable progress, yet approximately 490 mothers and more than 7,500 children under five years still die every day.As global health funding decreases, protecting decades of progress and continuing to build toward a healthier future will require tackling persistent bottlenecks, strengthening civil society advocacy, and coordinating leadership across sectors. What is needed now is bold, sustained political will to ensure every mother, newborn, and child survives and thrives.This published MNCH advocacy resource includes a Sub-Saharan Africa overview brief and country-specific briefs for Zambia, Uganda, Ethiopia, and Tanzania. Together, they outline key calls to action policymakers, funders, and advocates to accelerate the progress needed to improve health outcomes for mothers and children.

In this webinar, researchers from Burkina Faso and Mozambique shared learnings on how country-tailored interventions have helped increase the uptake of the malaria vaccine.As part of Gavi’s Malaria Vaccine Learning Agenda, experts presented findings and lessons learned from the rollout of malaria vaccines in Mozambique and Burkina Faso, sharing strategies to increase uptake through routine immunization platforms. This was the first in a quarterly series this year on learnings from malaria vaccine rollout in Africa.The session was co-moderated by Eleonora Genovese, Senior Programme Manager, Vaccine Programmes, Gavi, the Vaccine Alliance, and Saira Nawaz, Project Director, Primary Health Care, PATH. Featured speakers included Dr. Ali Sie, Centre de Recherche en Santé de Nouna (CRSN), Burkina Faso, and Daan Velthausz, Director, Maraxis BV, Mozambique.

This brief outlines the current state of health research and development (R&D) financing in Africa and underscores the importance of sustained, country-led investment amid declining global funding. Following a temporary surge during the COVID-19 pandemic, global health R&D financing has contracted significantly. In this context, the analysis frames domestic investment and governance of health R&D as contributors to health security and sovereignty, enabling countries to set national and regional priorities. Where predictable, country-led funding is absent, R&D pathways become fragmented, slowing product development and delaying patient access to lifesaving innovations.Against this backdrop, the brief highlights the need for more coordinated and resilient approaches to financing health R&D in Africa. Drawing on discussions co-hosted by PATH and Impact Global Health, it points to strong evidence that investment in health R&D generates substantial societal and economic returns, strengthens pandemic preparedness, and supports the development of local manufacturing capacity. The recommended actions collectively aim at building sustainable, Africa-led health R&D ecosystems.

Medical oxygen is a critical component of a well-functioning health system, yet only 30 percent of patients in low- and middle-income countries (LMICs) who need oxygen receive it. Key access barriers that drive this coverage gap include (1) supply and delivery challenges, such as limited production capacity, costly installation and maintenance requirements, and inadequate procurement and supply systems; (2) affordability, such as high cost of products and lack of local manufacturers; and (3) demand and adoption barriers, such as limited sustainable funding and limited guidelines.This fact sheet offers an overview of the INNOVATE project, which aims to address critical barriers to oxygen access. PATH, through a consortium of partners, will catalyze promising oxygen production and piping technologies, along with innovative operation and maintenance business models, to expand equitable access. By strengthening production and delivery capacity in health facilities and improving efficiency across the oxygen value chain, INNOVATE aims to accelerate the adoption of more cost-effective and sustainable solutions.